Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.47 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22466324 | 1.00 | ALOX5 (0.48) | ALOX5FFAR1GPR88HDAC4ALDH1A1 | |
| SCHEMBL3419041 | 1.00 | ALOX5 (0.48) | ALOX5FFAR1GPR88HDAC4ALDH1A1 | |
| SCHEMBL22492132 | 0.81 | ALOX5 (0.41) | ALOX5ALDH1A1TSHR | |
| SCHEMBL15091497 | 0.80 | ALOX5 (0.45) | ALOX5GPR88OPRK1TSHR | |
| SCHEMBL15091500 | 0.80 | ALOX5 (0.45) | ALOX5GPR88OPRK1TSHR | |
| SCHEMBL5217474 | 0.74 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1 | |
| SCHEMBL323823 | 0.74 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1 | |
| SCHEMBL323824 | 0.74 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1 | |
| SCHEMBL4126470 | 0.74 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1 | |
| SCHEMBL8295172 | 0.74 | FFAR1 (0.70) | FFAR1HDAC4ALDH1A1SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113614089-B | Morphinans useful in the treatment of medical conditions | 人福医药美国公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20220089605-A1 | NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-11214577-B2 | Morphinans useful for treating medical disorders | Humanwell Pharmaceutical US (US) | 2022-01-04 | — | — | US | disclosed |
| CN-113614089-A | Novel morphinans useful for treating medical conditions | 人福医药美国公司 | 2021-11-05 | — | — | CN | disclosed |
| WO-2020205735-A1 | NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS | Humanwell Pharmaceutical US (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200308185-A1 | NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | BRCA1, NAT1, AADAC | ALOX5 1793/4885FFAR1 3115/4885GPR88 1971/4885 |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | ALOX5 1386/4885FFAR1 3414/4885GPR88 2296/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | ALOX5 1386/4885FFAR1 3414/4885GPR88 2296/4885 |
| US-20200308185-A1 | NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS | OPRK1, OPRM1, OPRL1 | ALOX5 926/4885FFAR1 320/4885GPR88 230/4885 |
| US-11214577-B2 | Morphinans useful for treating medical disorders | OPRM1, OPRL1, OPRK1 | ALOX5 888/4885FFAR1 359/4885GPR88 317/4885 |
| US-20220089605-A1 | NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS | OPRK1, OPRM1, OPRL1 | ALOX5 926/4885FFAR1 320/4885GPR88 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.